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Unlikediabetesmellitusandimpairedglucosetolerance,itisnotclearwhetherthesubjectswithimpairedfastingglucose(IFG)are
at increased risk of atherosclerosis and cardiovascular diseases. The CD40-CD40 ligand interaction is involved in the mechanism
of atherosclerosis. We investigated whether soluble CD40L (sCD40L) as well as high sensitive C-reactive protein (hsCRP) levels are
increased in subjects with IFG having no confounding factors for inﬂammation or atherosclerosis. Twenty four IFG subjects with
no additional disorders and 40 appropriate healthy controls were studied. sCD40L and hsCRP levels in the IFG and control groups
were similar. Blood pressures, total and LDL-cholesterol, and triglyceride levels were also similar, whereas HDL-cholesterol was
lower and HOMA-IR indexes were higher in the IFG group. Though the sample size was small, the present data show that sCD40L
seems not to alter in subjects with IFG suggesting that it might not be an independent risk factor for atherosclerosis.
Copyright © 2006 Ilker Tasci et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Diabetes mellitus is a chronic progressive disease, which re-
sults in vascular complications due to macro- and microan-
giopathy [1]. Microangiopathy manifests itself as retinopa-
thy, nephropathy, and neuropathy, whereas macroangiopa-
thy is associated with accelerated atherosclerosis, which af-
fects coronary, carotid, and peripheral arteries, and results in
acute coronary syndrome, cerebrovascular disease, and pe-
ripheral vascular disease.
Impaired glucose tolerance (IGT) and impaired fasting
glucose(IFG)areintermediatemetabolicstatesbetweennor-
mal and diabetes mellitus [2]. Epidemiological data have
shown that the risk of cardiovascular diseases (CVDs) in-
creases linearly with increasing glycemia [3]. IGT has been
linkedtovascularcomplicationsbymanyauthors,whichwas
explained by the increase in 2-h glucose [4–6]. On the other
hand, whether the subjects with IFG are at increased risk of
vascular complications is not clear [7].
The CD40 ligand (CD40L), also known as CD154, is a
transmembrane-bound protein, which is found not only on
the cells of immunity but also on monocytes, macrophages,
platelets, and endothelial cells [8]. It initiates a variety of
inﬂammatory responses such as expression of cytokines,
proteases, or leukocyte adhesion molecules upon interaction
with CD40 receptor. Soluble and active forms of CD40 lig-
and (sCD40L) levels have been found to be increased in sev-
eral conditions associated with atherosclerosis such as acute
coronary syndrome [9], hypercholesterolemia [10], and IGT
and diabetes mellitus [11].
Giventheevidencesthatpostprandialhyperglycemiaand
IGT are major risks for future CVDs [4–6], we designed the
present study to investigate whether sCD40L as well as high
sensitive C-reactive protein (hsCRP) levels are increased in
individuals with IFG. In order to prevent any interference of
confounding factors for inﬂammation, we studied a group
having no additional disorders such as hypertension, dia-
betes mellitus, or obesity.
PATIENTS AND METHODS
Participants
Under the approval of the local ethics committee of Gulhane
Medical School and by obtaining written informed consent,
24 subjects with isolated IFG and 40 age-, sex-, and BMI-
matched healthy controls were studied.
The inclusion criteria for the participants were no his-
tory of any metabolic or inﬂammatory disorders, absence2 Mediators of Inﬂammation
of dyslipidemia [low-density lipoprotein (LDL)-cholesterol
< 130mg/dl], hypertension (systolic blood pressure < 140
mmHg and diastolic blood pressure < 90mmHg), obesity
[body mass index (BMI) < 30kg/m2], clinical evidence for
either cardiovascular or peripheral artery diseases (history
of acute myocardial infarction, coronary angioplasty, or by-
pass surgery, symptoms of angina, dyspnea, or claudicatio,
and electrocardiographic abnormality) as well as rheumatic
diseases, renal, hepatic, or thyroid dysfunction, concomitant
medications(includingherbal),regularalcohol,ordrugcon-
sumption, smoking, and pregnancy. All subjects underwent
a detailed physical examination and gave blood samples.
Anthropometricmeasurements
Weight and height were measured without shoes and in light
clothing. BMI was calculated as weight divided by squared
height (kg/m2). Systolic and diastolic blood pressures were
measured using a manual mercury sphygmomanometer.
Two readings were obtained ﬁve minutes apart in the sitting
position, and the mean of the two was recorded as the blood
pressure.
Deﬁnitionofglucosetolerancestatus
All participants underwent standard oral glucose tolerance
test (OGTT) according to the American Diabetes Associa-
tion criteria [2]. A high-carbohydrate diet was applied three
days before the test. At the baseline, blood was drawn un-
der 12-hour fasting conditions in the morning. Then, 75g
glucose solution was given orally and a second venipuncture
was performed 2 hours after the challenge. Normal glucose
tolerance was deﬁned as a fasting and 2-hour plasma glucose
of < 100mg/dl and < 140mg/dl, respectively. IFG was de-
ﬁned as fasting plasma glucose of 100–126mg/dl and 2-hour
plasma glucose of < 140mg/dl. Fasting plasma glucose of
100–126mg/dl and 2-hour plasma glucose of 140–200mg/dl
were accepted as IGT. All the study and control subjects en-
rolled in the study had only isolated IFG or normal glucose
tolerance.
Biochemicalparameters
For biochemical analyses, all the serum samples were drawn
between 08 : 00 and 08 : 30AM after a 12-hour fasting.
The tubes were promptly centrifuged, and the plasma was
separated and stored at −70◦C. All plasma samples were
run in the same assay. Glucose, total cholesterol, triglyceride
(TG), and high-density lipoprotein (HDL)-cholesterol levels
were measured by the enzymatic colorimetric method with
OlympusAU600autoanalyzerusingreagentsfromOlympus
Diagnostics, (GmbH, Hamburg, Germany). LDL-cholesterol
was calculated by Fridewald’s formula (12). The serum basal
insulinwasmeasuredinduplicatebythecoatedtubemethod
(DPC-USA).
Insulin resistance was calculated by homeostasis model
assessment model (HOMA) using the formula HOMA-IR =
Fasting insulin (μU/ml) × Fasting glucose (mg/dl)/405 [12].
Low-IRvaluesindicatehighinsulinsensitivity,whereashigh-
HOMA values indicate low insulin sensitivity (insulin resis-
tance).
sCD40LandhsCRP
Human sCD40L was measured by ELISA (Quantikine, R &
D Systems Inc, Minneapolis, USA) [sensitivity: (minimum
detectable concentration) = 0.095ng/ml, intraCV: 4.0% and
interCV: 6.8%]. Serum hsCRP was determined by turbidi-
metric ﬁxed rate method [13] by an automated analyzer
(Olympus AU-2700, Mishima, Japan). Both tests were run
in duplicate.
Statisticalanalysis
Results are reported as the mean ± SD and median (for the
skewed data). Diﬀerences between prediabetic and control
groups were tested for signiﬁcance by independent samples
Student t test and Mann-Whitney U test. Diﬀerences were
considered signiﬁcant at P<. 05. Because there has been no
former data regarding sCD40L levels in such a study popu-
lation, the sample size was not calculated by power analysis.
The power of the study was calculated according to the re-
sults in the two groups.
RESULTS
The mean age, gender, BMI, blood pressure, fasting glu-
cose,andplasmalipids oftheparticipants aresummarizedin
Table 1. Both groups had similar distribution of age, sex, and
BMI. Systolic and diastolic blood pressures were also similar
in the two groups.
Soluble CD40L levels in subjects with IFG and healthy
controls were not diﬀerent (P = .14) (Figure 1). hsCRP lev-
els were also comparable in the two groups (P = .29). To-
tal cholesterol, LDL-cholesterol, and TG levels were similar
(P = .40, P = .67, and P = .31, resp), whereas HDL choles-
terol concentration was lower (P<. 001) in the IFG group
comparedtocontrols.HOMAindexeswerehigherintheIFG
g r o u pa sw e l l( P<. 001).
The power of the study was calculated according to the
results and found 0.57 for sCD40L, 0.71 for hsCRP, and 0.92
for HOMA.
DISCUSSION
In the present study, subjects with IFG had similar plasma
sCD40L concentrations when compared to healthy individu-
als with normal glucose tolerance. hsCRP levels were not sig-
niﬁcantly diﬀerent in the two groups as well. However, high
levels of HOMA indexes indicated an insulin-resistant state
in the IFG group.
Although IGT and IFG are not considered to be “dis-
eases,”theyareassociatedwithincreasedriskofdevelopment
of overt diabetes mellitus [14], a true risk factor for morbid-
ity, and mortality from CVDs [15]. However, the association
between glucose status and the risk of CVDs starts below theIlker Tasci et al 3
Table 1: Comparison of characteristics and laboratory ﬁndings of the subjects with IFG and healthy controls. Data are expressed as mean
value ± SD, median (min-max).
IFG (n = 24) Controls (n = 40) P
Age (y) 46.6 ±5.54 7 .4 ±7.5 .64†
Gender (male/female) 10/14 17/23 .13∗
Body mass index (kg/m2) 28.3 ±3.32 7 .7 ±4.0 .57†
Systolic blood pressure (mmHg) 125.4 ±8.6 128.4 ±8.9 .85†
Diastolic blood pressure (mmHg) 80.1 ±9.08 0 .2 ±5.4 .44†
Total cholesterol (mg/dl) 199.5 ±43.5 208.6 ±36.7 .40†
HDL-cholesterol (mg/dl) 37.5 (31–69) 49 (34–77) <. 001‡
LDL-cholesterol (mg/dl) 129.5 (79–221) 127 (65–203) .67‡
Triglyceride (mg/dl) 137.5 (65–447) 118 (50–397) .31‡
Fasting glucose (mg/dl) 110.7 ±8.17 7 .5 ±8.3 <. 001†
hsCRP (mg/l) 1.93 (0.43–4.1) 1.34 (0.22–4.0) .29‡
HOMA-IR 2.47 (0.84–5.8) 1.34 (0.58–2.71) <. 001‡
sCD40L (ng/ml) 1.0( 0 .04–3) 1.47 (0.26–2.11) .14‡
† Independent sample Student t test, ‡ Mann-Whitney U test, ∗ Chi-square test.
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Figure 1:sCD40L(ng/mL)andhsCRP(mg/L)concentrationswere
similar, whereas HOMA-IR indexes were signiﬁcantly higher in the
IFG group in comparison with controls.
diagnostic threshold for diabetes mellitus [6]. Since 2-h glu-
cose levels are known to increase the risk of vascular com-
plications, IGT is considered to be a risk factor for CVDs
[5]. However, the data related to the CVD risk in people
with IFG are controversial. While several studies reported
that even fasting hyperglycemia is associated with increased
mortality (17–19), others concluded with less impressive re-
sults regarding an increased CVD risk in subjects with IFG
[7,16].Theworseeﬀectsofpostprandialhyperglycemiathan
fasting plasma glucose on atherosclerosis and related events
havebeendeﬁnedbyseveralmechanisms.Increasedglycemia
results in formation of intracellular reactive oxygen species
[17] and advanced glycation end products (AGEs) from pro-
teins and lipids in and outside the cells [18]. AGEs stimu-
lation causes increased synthesis of reactive oxygen species
in endothelial cells, proliferation of smooth muscle cells, de-
creased nitric oxide-mediated vasodilatation responses, as
well as activation of mononuclear cells of immunity [18].
AGEs have also nonreceptor-mediated eﬀects especially on
extracellularmatrixproductioninthevesselwall[19].Aswas
shown in people with IGT, hyperglycemia-induced oxidative
stress triggers production of proinﬂammatory cytokines in-
cluding hsCRP [20], which is an independent risk factor for
future cardiovascular events [21]. Clinically, postchallenge
hyperglycemiawasreportedtocauseendothelialdysfunction
together with increase in markers of oxidative stress [22],
and related more strongly than fasting plasma glucose with
carotid intima media thickness [23].
On the other hand, besides the evidence of harmful ef-
fectsofpostprandialhyperglycemia,theweakassociationbe-
tween IFG and cardiovascular mortality in several studies
might have been resultant from the unadjustment of clus-
tering eﬀects of other risk factors such as hypertension, dys-
lipidemia, obesity, or smoking. Determination of the global
risk of IFG should include analyses of the other risk fac-
tors. Therefore, though the number of the study popula-
tion is small, the present investigation addresses this ques-
tion in a group of people with IFG having no confounders
for atherosclerosis, and supports the results of previous stud-
ies [7, 16] concluding with no increase in the risk of CVDs in
this category of glucose intolerance.
Endothelial dysfunction, usually induced by dyslipide-
mia, is one of the earliest events in the development of
atherosclerosis, and inﬂammation is involved in the mech-
anism of atherosclerosis from the early phases [24]. Macro-
phages, upon activation by oxidized LDL, release a vari-
ety of substances such as cytokines and growth factors in-
cluding tumor necrosis factor (TNF)-α, interleukins (ILs),
and sCD40L [25]. CD40L, which is not only expressed
on macrophages but also synthesized by activated CD4 +
cells, mast cells, basophils, eosinophils, and natural killer
cells as well as endothelial cells, smooth muscle cells and
platelets [8], is subsequently cleaved over a period of
minutes to hours, generating a soluble fragment termed
sCD40L, the biologically active form having similar proin-
ﬂammatory eﬀects on vascular cells [8]. Atherosclerosis and
plaque formation is the result of chronic inﬂammation and4 Mediators of Inﬂammation
wound-healing response, and CD40-CD40L system is a key
regulator of communication between the cells of immunity
in this process [26]. Engagement of CD40 with its ligand on
the above-mentioned cells results in production of potent
proinﬂammatory cytokines such as IL-1, IL-6, and IL-8 as
well as increase in production of extracellular matrix and its
proteases [26].
HighplasmaconcentrationsofsCD40Lwereproposedto
be associated with increased vascular risk. Increased sCD40L
was reported in patients with coronary heart disease [9],
coronary restenosis after PTCA [27], and dyslipidemia [10].
Recently, it was also reported that, as the patients with dia-
betes mellitus, otherwise healthy people with IGT have in-
creased plasma sCD40L levels when compared to controls
[11]. In the present investigation, subjects with IFG who had
no confounders for CVDs or inﬂammation did not have sig-
niﬁcant increase in sCD40L in their plasma. Given the evi-
dences that postchallenge but not the fasting plasma glucose
has stronger impacts on the risk of atherosclerosis and fu-
ture cardiovascular events that are commonly accompanied
by alterations in markers of chronic inﬂammation, we sug-
gest that the people with IFG may not be under signiﬁcant
risk of CVDs unless their 2-hour glucose tolerance worsens.
Besides sCD40L, the normal hsCRP levels in the IFG group
further support this idea because hsCRP is a reliable marker
for inﬂammation and is a predictor of future cardiovascular
events [21].
In the present investigation, although their BMI, total
cholesterol, triglyceride, sCD40L, and hsCRP concentrations
were similar, the people with IFG were more insulin resis-
tant than the controls. Subjects with IFG were reported to
have tendency to be more insulin resistant than those with
IGT [28, 29]. Insulin resistance is a component of metabolic
syndrome, a condition associated with atherosclerotic dis-
eases [30]. However, current data related to an association of
serum levels of inﬂammatory markers and structural indica-
tors of atherosclerosis with insulin sensitivity is not clear. In-
sulinresistancecalculatedeitherbyHOMAformulaorintra-
venous glucose tolerance test was reported to correlate with
CRP in people with IGT [31], indicating that the presence of
resistance to biologic activity of insulin increases the risk of
future cardiovascular events. On the other hand, it was also
reported that insulin resistance correlates more strongly with
hsCRP when present as part of insulin resistance syndrome
[32], suggesting the common pathophysiological impacts of
the determinants of the metabolic syndrome on atheroscle-
rosis.However,severalstudiesfocusingonthecarotidintima
media thickness in nondiabetic subjects with [33] or without
[34] glucose dysregulation concluded with no signiﬁcant in-
crease in structural ﬁndings of atherosclerosis in people with
insulin resistance. Therefore, the interrelation between in-
sulin resistance and serum markers of inﬂammation in peo-
ple with IFG having no other components of metabolic syn-
drome or confounding factors for atherosclerosis should be
further determined.
We found in our group of IFG that HDL cholesterol
concentration was signiﬁcantly lower compared to controls,
whereas triglycerides as well as total and LDL cholesterol
were similar. Igarashi et al have reported a decrease in HDL
concentration as the glucose tolerance worsens in people
withIGT[35].OurresultsmayindicatethatdecreaseinHDL
concentration starts early in the course of glucose intoler-
ance. However, low HDL-cholesterol levels are not always ac-
companied by a predisposition to premature coronary heart
disease [36]. Though an inverse correlation between HDL
and CRP was previously described in patients with cardio-
vascular or atherosclerotic diseases [37], increased total and
LDL cholesterol levels more strongly relate to atherosclerosis
[38]. Nevertheless, more is needed to identify the prognos-
tic importance of individual alterations in lipid proﬁle and
their association with inﬂammation markers in people with
IFG.
Though the study population and the controls enrolled
were selected speciﬁcally, the present study has two limita-
tions. First, due to the narrow selection criteria the sam-
ple size was small to represent all people with IFG. Second,
though it is simple, noninvasive, and known to be correlated
well with clamp test [12], the HOMA formula used to calcu-
late insulin sensitivity in this work is only an estimate and
cannot be as accurate as the euglycemic hyperinsulinemic
clamp method.
In conclusion, the results of the present study suggest
no alterations in sCD40L as well as hsCRP levels in subjects
with IFG, which contribute to the data that IFG alone might
not be an independent risk factor for atherosclerosis. Studies
with larger populations may provide further information re-
garding CD40-CD40L system and its interaction with other
predictors of atherosclerosis in people with IFG.
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